AR115464A1 - Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau - Google Patents
Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tauInfo
- Publication number
- AR115464A1 AR115464A1 ARP190101480A ARP190101480A AR115464A1 AR 115464 A1 AR115464 A1 AR 115464A1 AR P190101480 A ARP190101480 A AR P190101480A AR P190101480 A ARP190101480 A AR P190101480A AR 115464 A1 AR115464 A1 AR 115464A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- formula
- compounds
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000001721 carbon Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- -1 or any two of Rd Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o estereoisómeros, mezclas racémicas, tautómeros, sales aceptables desde el punto de vista farmacéutico de este; en donde A se selecciona del grupo que consiste en los compuestos del grupo de fórmulas (2), en donde estos compuestos del grupo de fórmula (2) pueden estar unidos al átomo de N en cualquier posición disponible, y en donde los compuestos del grupo de fórmulas (3) están sustituidos con uno o más sustituyentes Rʲ; B se selecciona del grupo que consiste en O y NRᵃ; E y V se seleccionan independientemente del grupo que consiste en N, NR⁵, O y S; G se selecciona del grupo que consiste en un anillo de benceno y un anillo de piridina; J se selecciona del grupo que consiste en O, N-R¹ y CH₂ o J se selecciona del grupo que consiste en CH o C si J está unido a R²; Y, Y¹, Y² y Y³ son CZ; Z se selecciona independientemente del grupo que consiste en H, halógeno, O-alquilo, alquilo y CN; R se selecciona independientemente del grupo que consiste en el resto de fórmula (4) y -NR³R⁴; Rᵃ se selecciona del grupo que consiste en H y alquilo; Rᵈ, Rᵉ, Rᶠ, y Rᵍ se seleccionan independientemente del grupo que consiste en H y alquilo, o dos cualquiera de Rᵈ, Rᵉ, Rᶠ, Rᵍ se pueden unir para formar un anillo de 3 a 8 miembros; Rʲ se selecciona independientemente del grupo que consiste en -halógeno, -O-alquilo, -NR³R⁴, -CN, un resto de fórmula (5), de fórmula (6) y de fórmula (7), en donde un puente o un enlace que contiene un átomo de C₁₋₂ carbono puede estar presente entre el átomo de carbono a y el átomo de carbono c o d o en donde un puente o un enlace que contiene un átomo de C₁₋₂ carbono puede estar presente entre el átomo de carbono b y el átomo de carbono c o d; R¹ se selecciona del grupo que consiste en H y alquilo; R² se selecciona independientemente del grupo que consiste en alquilo, u -O-alquilo y en donde si dos R² son geminales entonces se pueden unir para formar un anillo de 3 a 6 miembros; R³ y R⁴ se seleccionan independientemente del grupo que consiste en H y alquilo; R⁵ se selecciona del grupo que consiste en H y alquilo; n es 0, 1, 2, 3 ó 4; r y s son independientemente 0, 1, 2, ó 3; y t y u son independientemente 1, 2 ó 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18175845 | 2018-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115464A1 true AR115464A1 (es) | 2021-01-20 |
Family
ID=62530123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101480A AR115464A1 (es) | 2018-06-04 | 2019-05-31 | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau |
Country Status (14)
Country | Link |
---|---|
US (2) | US11684625B2 (es) |
EP (1) | EP3802533A1 (es) |
JP (1) | JP7357371B2 (es) |
KR (1) | KR102550423B1 (es) |
CN (1) | CN112351984B (es) |
AR (1) | AR115464A1 (es) |
AU (1) | AU2019280590B2 (es) |
BR (1) | BR112020022245A2 (es) |
CA (1) | CA3102343C (es) |
EA (1) | EA202092557A1 (es) |
IL (1) | IL279106A (es) |
MX (1) | MX2020013115A (es) |
TW (1) | TWI743484B (es) |
WO (1) | WO2019233883A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3931189A4 (en) * | 2019-02-27 | 2022-11-30 | The Regents Of The University Of California | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS |
CN113453688A (zh) * | 2019-03-01 | 2021-09-28 | Ac免疫有限公司 | 用于治疗、减轻或预防与Tau聚集体相关的病症的新化合物 |
JP2023530664A (ja) * | 2020-06-10 | 2023-07-19 | デリックス セラピューティクス,インク. | 三環系サイコプラストゲンおよびその使用 |
WO2022232007A1 (en) * | 2021-04-25 | 2022-11-03 | University Of Notre Dame Du Lac | Modified peptides for the inhibition of abnormal tau accumulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136493A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
CA2641670A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
EP2220083B1 (en) * | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
DK2558446T5 (da) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
US9714245B2 (en) * | 2013-06-28 | 2017-07-25 | Alzprotect | Carboline compounds usable in the treatment of neurodegenerative diseases |
CN107216327A (zh) | 2017-06-27 | 2017-09-29 | 山东大学 | 5型磷酸二酯酶抑制剂及其制备方法和用途 |
-
2019
- 2019-05-30 EP EP19730702.8A patent/EP3802533A1/en active Pending
- 2019-05-30 MX MX2020013115A patent/MX2020013115A/es unknown
- 2019-05-30 WO PCT/EP2019/064144 patent/WO2019233883A1/en active Application Filing
- 2019-05-30 KR KR1020207034883A patent/KR102550423B1/ko active IP Right Grant
- 2019-05-30 BR BR112020022245-3A patent/BR112020022245A2/pt unknown
- 2019-05-30 TW TW108118763A patent/TWI743484B/zh active
- 2019-05-30 US US17/053,459 patent/US11684625B2/en active Active
- 2019-05-30 AU AU2019280590A patent/AU2019280590B2/en active Active
- 2019-05-30 EA EA202092557A patent/EA202092557A1/ru unknown
- 2019-05-30 CN CN201980037185.4A patent/CN112351984B/zh active Active
- 2019-05-30 JP JP2020566895A patent/JP7357371B2/ja active Active
- 2019-05-30 CA CA3102343A patent/CA3102343C/en active Active
- 2019-05-31 AR ARP190101480A patent/AR115464A1/es unknown
-
2020
- 2020-11-30 IL IL279106A patent/IL279106A/en unknown
-
2023
- 2023-04-04 US US18/295,667 patent/US20230255976A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI743484B (zh) | 2021-10-21 |
AU2019280590B2 (en) | 2022-11-17 |
EP3802533A1 (en) | 2021-04-14 |
TW202017924A (zh) | 2020-05-16 |
AU2019280590A1 (en) | 2020-11-19 |
KR20210005724A (ko) | 2021-01-14 |
KR102550423B1 (ko) | 2023-07-04 |
US20210267989A1 (en) | 2021-09-02 |
CN112351984A (zh) | 2021-02-09 |
WO2019233883A1 (en) | 2019-12-12 |
EA202092557A1 (ru) | 2021-04-01 |
CA3102343A1 (en) | 2019-12-12 |
IL279106A (en) | 2021-01-31 |
US20230255976A1 (en) | 2023-08-17 |
JP2021525272A (ja) | 2021-09-24 |
US11684625B2 (en) | 2023-06-27 |
CN112351984B (zh) | 2024-01-02 |
BR112020022245A2 (pt) | 2021-02-02 |
CA3102343C (en) | 2023-08-29 |
JP7357371B2 (ja) | 2023-10-06 |
MX2020013115A (es) | 2021-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR115464A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
HRP20080608T3 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR109829A1 (es) | Derivados de piperidina puenteados | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
AR115936A1 (es) | Compuestos útiles en terapia del vih | |
AR116400A1 (es) | Compuesto de imidazopiridinona | |
AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor |